FacebookTwitterGoogle+RedditEmail

The Penalties for Political Corruption in China and the US

by CORPORATE CRIME REPORTER

Zheng Xiaoyu meet Lester Crawford.

Lester Crawford is the former head of the U.S. Food and Drug Administration (FDA).

Zheng Xiaoyu is the former head of China’s equivalent of the FDA.

Both have been convicted of crimes committed while in office.

Earlier this week, Zheng was sentenced to death.

Earlier this year, Crawford was sentenced to three years probation.

Zheng was sentenced to death for allegedly pocketing bribes from drug makers seeking fast track approval.

Zheng allegedly took cash and gifts from eight companies, either personally or routed through his wife and son, for approving fake medicine.

Zheng was convicted of the charges after a ten-day closed door trial.

And sentenced to death.

It was a political trial and a political sentence that came on the heels of news stories that threatened China’s export-driven economy.

What was concerning China’s political leadership?

Was it the bribery?

Was it the babies that died of malnutrition in Anhui province in 2004 after they were fed fake milk powder with no nutritional value?

Was it the antibiotic approved by the food and drug agency during Zheng’s tenure that killed at least 10 patients in 2006 before it was taken off the market?

No, no, and no.

It was the dead dogs and cats in the United States that were dying from contaminated pet food from China.

It was the exported contaminated toothpaste that contained a chemical used in antifreeze.

It was the Chinese medical products linked to deaths in Panama.

The news of exports from China killing abroad threatened the foundations of the Chinese economy.

And someone had to pay the price.

That would be Zheng Xiaoyu.

What message does our system send when the former head of our FDA gets his industry ties caught in the Justice Department’s grinder?

No jail.

Three years probation.

$90,000 fine.

Nice paying job at a pharma consulting firm.

Even a keynote address at Harvard University later this year on the topic of FDA compliance.

That of course would be the case of former FDA chief Lester Crawford.

It wasn’t his corporate ideology that got former Crawford in trouble last year.

It was trying to hide the extent of his corporate connections.

In October 2007, Crawford pled guilty to charges that he hid his ownership in stock in food and drug companies that the FDA regulates. He was sentenced earlier this year to three years probation and fined $90,000.

For the past year or so, Crawford has worked at a consulting firm, Policy Directions.

And he’s scheduled to appear as a keynote speaker later this year at the FDA Regulatory and Compliance Symposium at Harvard University.

Dr. Steve Nissen, for one, is troubled by the extent of the pharmaceutical industry’s ties to federal cops on the corporate crime beat.

Nissen is chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic Foundation.

He is concerned about the “imbalance of power between the FDA and industry.”

“When drug studies reveal toxicity or lack of efficacy, the FDA is not permitted to release the results and the findings are often not published, thereby denying patients and physicians access to vitally important safety information,” Nissen said in little reported comments last year at the National Press Club in Washington, D.C.

The reason?

Conflicts of interest at the highest levels of the FDA.

The entire FDA budget for drug regulation is about $500 million and relies extensively on pharmaceutical industry user fees, Dr. Nissen said.

As a result, the FDA is financially indebted to the companies it must regulate.

Nissen pointed to Dr. Scott Gottlieb, who was sitting right next to him at the National Press Club event.

Gottlieb was deputy FDA commissioner at the time. He later resigned to join the corporate funded American Enterprise Institute.

“For years, we had an interim FDA Commissioner, Lester Crawford, who shortly after confirmation, abruptly resigns, apparently because he and his wife owned stock in regulated companies,” he says.

“Then the administration appointed Andrew Von Eschenbach as interim commissioner, creating another conflict,” Dr. Nissen says. “In his role as director of the National Cancer Institute, Von Eschenbach must seek FDA approval for human testing or approval of new cancer drugs, an obvious conflict.”

“Even worse, the administration appointed Scott Gottlieb as deputy commissioner,” Dr. Nissen says. “He came to this job with no regulatory experience, directly from Wall Street, where he served as a biotech analyst and stock promoter. Between them, Drs. Von Eschenbach and Gottlieb have whined incessantly about the need to speed drug development. So while the American people worry about the safety of drugs, the top FDA leadership tells us we need faster drug approval.”

When asked about his industry connections, Gottlieb said that he complied with all legal requirements.

But that wasn’t Nissen’s point.

It’s legal in the United States for the pharmaceutical companies to take over the FDA.

No death penalty needed.

CORPORATE CRIME REPORTER is located in Washington, DC. They can be reached through their website

 

 

More articles by:

CounterPunch Magazine

minimag-edit

bernie-the-sandernistas-cover-344x550

zen economics

Weekend Edition
December 09, 2016
Friday - Sunday
Jeffrey St. Clair
Roaming Charges: Nasty As They Wanna Be
Henry Giroux
Trump’s Second Gilded Age: Overcoming the Rule of Billionaires and Militarists
Andrew Levine
Trump’s Chumps: Victims of the Old Bait and Switch
Erin McCarley
American Nazis and the Fight for US History
Lewis Lapham
Hostile Takeover
Joshua Frank
This Week at CounterPunch: More Hollow Smears and Baseless Accusations
Paul Street
The Democrats Do Their Job, Again
Vijay Prashad
The Cuban Revolution: Defying Imperialism From Its Backyard
Michael Hudson - Sharmini Peries
Orwellian Economics
Mark Ames
The Anonymous Blacklist Promoted by the Washington Post Has Apparent Ties to Ukrainian Fascism and CIA Spying
Conn Hallinan
India & Pakistan: the Unthinkable
Andrew Smolski
Third Coast Pillory: Nativism on the Left – A Realer Smith
Joshua Sperber
Trump in the Age of Identity Politics
Brandy Baker
Jill Stein Sees Russia From Her House
Katheryne Schulz
Report from Santiago de Cuba: Celebrating Fidel’s Rebellious Life
Nelson Valdes
Fidel and the Good People
Norman Solomon
McCarthy’s Smiling Ghost: Democrats Point the Finger at Russia
Renee Parsons
The Snowflake Nation and Trump on Immigration
Margaret Kimberley
Black Fear of Trump
Michael J. Sainato
A Pruitt Running Through It: Trump Kills Nearly Useless EPA With Nomination of Oil Industry Hack
Ron Jacobs
Surviving Hate and Death—The AIDS Crisis in 1980s USA
David Swanson
Virginia’s Constitution Needs Improving
Louis Proyect
Narcos and the Story of Colombia’s Unhappiness
Paul Atwood
War Has Been, is, and Will be the American Way of Life…Unless?
John Wight
Syria and the Bodyguard of Lies
Richard Hardigan
Anti-Semitism Awareness Act: Senate Bill Criminalizes Criticism of Israel
Kathy Kelly
See How We Live
David Macaray
Trump Picks his Secretary of Labor. Ho-Hum.
Howard Lisnoff
Interview with a Political Organizer
Yves Engler
BDS and Anti-Semitism
Martha Durkee-Neuman
Millennial Organizers Want to See An Intersectional Understanding Of Gun Violence
Adam Parsons
Home Truths About the Climate Emergency
Brian Cloughley
The Decline and Fall of Britain
Eamonn Fingleton
U.S. China Policy: Is Obama Schizoid?
Graham Peebles
Worldwide Air Pollution is Making us Ill
Joseph Natoli
Fake News is Subjective?
Andre Vltchek
Tough-Talking Philippine President Duterte
Binoy Kampmark
Total Surveillance: Snooping in the United Kingdom
Guillermo R. Gil
Vivirse la película: Willful Opposition to the Fiscal Control Board in Puerto Rico
Patrick Bond
South Africa’s Junk Credit Rating was Avoided, But at the Cost of Junk Analysis
Clancy Sigal
Investigate the Protesters! A Trial Balloon Filled With Poison Gas
Charles R. Larson
Review:  Helon Habila’s The Chibok Girls: the Boko Haram Kidnappings and Islamist Militancy in Nigeria
December 08, 2016
John W. Whitehead
Power to the People: John Lennon’s Legacy Lives On
Mike Whitney
Rolling Back the Empire: Washington’s Proxy-Army Faces Decisive Defeat in Aleppo
Ellen Brown
“We’ll Look at Everything:” More Thoughts on Trump’s $1 Trillion Infrastructure Plan
FacebookTwitterGoogle+RedditEmail